Pfizer Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PFE research report →
Range $27 – $40
Price Chart
About the company
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis.
- CEO
- Albert Bourla
- IPO
- 1972
- Employees
- 75,000
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on PFE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $156.18B
- P/E
- 38.96
- Fwd P/E
- 8.97
- PEG
- -0.66
- P/S
- 2.47
- P/B
- 1.76
- EV/EBITDA
- 16.17
- Div Yield
- 6.25%
- Gross Margin
- 73.37%
- Op Margin
- 23.83%
- Net Margin
- 6.34%
- ROE
- 4.60%
- ROIC
- 8.26%
Latest fiscal year · YoY change
- Revenue
- $62.58B-1.6%
- Gross Profit
- $46.51B+1.6%
- Op Income
- $17.41B
- Net Income
- $7.77B-3.2%
- EPS
- $1.36-4.2%
- OCF Growth
- -8.2%
- FCF Growth
- -7.7%
- 52W High
- $31.44
- 52W Low
- $23.62
- 50D MA
- $28.83
- 200D MA
- $27.02
- Beta
- 0.30
- RSI (14)
- 34
- Avg Volume
- 33.50M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Pfizer reported a better-than-expected third quarter, raised 2026 revenue and EPS guidance, and pointed to stronger non-COVID growth, improving margins, and a deepening late-stage pipeline.· November 3, 2026
- Q3 revenue was $61.7 billion, above expectations, with reported diluted EPS of $0.56 and adjusted diluted EPS of $0.87.
- Non-COVID products grew 7% operationally in the quarter, while launched and acquired products grew 32% operationally to $3.8 billion.
- Management raised full-year 2026 revenue guidance to $62 billion-$64 billion and raised/narrowed adjusted diluted EPS guidance to $2.95-$3.05.
- Adjusted gross margin was 77% and adjusted operating margin was 36%, helped by mix and cost discipline.
- Pipeline updates were constructive across obesity, oncology, immunology, and vaccines, with several Phase 3 starts and readouts expected over the next 12 months.
Pfizer reported third quarter 2026 revenue of $61.7 billion, above its expectation. Reported diluted EPS was $0.56, and adjusted diluted EPS was $0.87, which included a $0.10 charge related to the Innovent transaction. Non-COVID products delivered 7% operational growth in the quarter, while launched and acquired products grew 32% operationally to $3.8 billion; COVID-19 product revenue declined. Adjusted gross margin was 77%, and adjusted operating margin was 36%. For full-year 2026, Pfizer raised revenue guidance to $62 billion-$64 billion, reaffirmed about $4 billion of COVID product revenue, guided to R&D expense of $10.8 billion-$11.8 billion, and raised and narrowed adjusted diluted EPS guidance to $2.95-$3.05. Management also said it remains on track to deliver nearly all of the anticipated $7.2 billion of net savings by end-2026, with an additional $2.5 billion of net cost savings expected from 2027 through 2029.
Albert Bourla framed the quarter as another strong one, emphasizing commercial execution, financial discipline, and ongoing productivity gains as the basis for improved margins and raised guidance. He highlighted the 32% operational growth in launched and acquired products, the expansion of the oncology franchise through Seagen, and progress in obesity and other late-stage programs. His tone was confident and forward-looking, with repeated emphasis that Pfizer is positioned for growth toward the end of the decade and for a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033.
Cecile Guegan said the quarter showed continued commercial execution and financial discipline, with non-COVID growth, product mix, and cost management supporting margin expansion. She cited $61.7 billion of revenue, $0.56 reported EPS, $0.87 adjusted EPS, 77% adjusted gross margin, 36% adjusted operating margin, and $3.8 billion of launched/acquired product revenue growing 32% operationally. She also said Pfizer expects nearly all of the $7.2 billion in net savings by end-2026, plus another $2.5 billion from 2027-2029, ended the quarter with leverage of 2.6x versus a 2026 target of 2.7x, and generated $8.8 billion of operating cash flow in the first nine months of 2026 while returning $7.3 billion to shareholders via dividends.
Analysts focused on pipeline positioning, pricing/340B dynamics, cost savings, capital allocation, and 2027 drivers. Management said gross-to-net was not materially different in Q3 aside from the expected Eliquis impact from the January WAC decrease, and that it would reflect IRA, 340B, and MFN dynamics in 2027 guidance. On cost, Cecile said the first-phase $7.2 billion savings plan remains on track and that the new $2.5 billion program is intended to help offset LOE-related margin pressure in 2027-2029. On pipeline, Pfizer said tilrekimig is in Phase 3 with AD readouts and COPD/asthma programs starting, berobenatide is being developed first for obesity with additional studies to come, and MEVPRO-1 is now expected in Q1 2027, with MEVPRO-2 in Q4 2027.
The call suggested Pfizer is getting real commercial lift from acquired assets and key brands, not just from cost cuts: launched/acquired products grew 32% operationally and several products showed strong demand. Management also sounded encouraged by multiple pipeline assets, including Elrexfio, tilrekimig, and obesity programs, with several Phase 3 starts and readouts ahead. The raised full-year guide and comments about margin support from productivity initiatives reinforce the case that earnings and growth may improve as the pipeline matures.
The main risks remain LOE pressure, especially in 2027-2029, with management explicitly citing Ibrance, Xtandi, and Eliquis as headwinds and saying leverage may stay around current levels or modestly higher during the transition. COVID product sales are still declining and the quarter’s growth remains dependent on non-COVID execution. Several pipeline assets are still early or in development, and management acknowledged that some key value creation, including obesity and oncology opportunities, depends on future clinical and regulatory success.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 5.70B
- Float Shares
- 5.69B
of shares held by institutions
2,978 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for PFE, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 25, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Carol Devine MillerHouse · WV01 | Sell | Mar 10, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 7, 26 | Filing → |
| Michael RulliHouse | Sell | Nov 26, 24 | Filing → |
| Alan ArmstrongSenate | Sell | Mar 24, 26 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Jun 8, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Mar 13, 26 | Filing → |
| Susan Margaret CollinsSenate · ME | Buy | Feb 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Feb 10, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 541.35M | ▲ 7.03M |
| Blackrock, Inc. | 521.03M | ▼ 8.64M |
| Vanguard Capital Management LLC | 373.00M | ▲ 852.66K |
| State Street Corp | 309.57M | ▲ 2.48M |
| Geode Capital Management, LLC | 137.51M | ▲ 2.23M |
| Vanguard Portfolio Management LLC | 120.47M | ▲ 1.24M |
| Fisher Asset Management, LLC | 112.12M | ▲ 3.05M |
| Morgan Stanley | 96.93M | ▲ 586.25K |
| Massachusetts Financial Services Co | 64.61M | ▲ 8.05M |
| Norges Bank | 61.51M | ▲ 61.51M |
| Northern Trust Corp | 58.90M | ▼ 182.56K |
| State Farm Mutual Automobile Insurance Co | 54.51M | 0 |
Held by 2,108 ETFs
Biggest fund positions in PFE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | BOURLA ALBERT | other | 21 |
| Oct 30, 26 | BOURLA ALBERT | other | 20 |
| Oct 15, 26 | BOURLA ALBERT | other | 20 |
| Oct 13, 26 | BOURLA ALBERT | other | 71 |
| Sep 30, 26 | BOURLA ALBERT | other | 21 |
| Sep 25, 26 | Buckley Mortimer J | other | 1,307.987 |
| Sep 25, 26 | Echevarria Joseph | other | 1,613.185 |
| Sep 25, 26 | NARAYEN SHANTANU | other | 1,743.983 |
| Sep 25, 26 | Quincey James | other | 1,351.587 |
| Sep 25, 26 | SMITH JAMES C | other | 1,569.585 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PFE coverage
Recent articles, reports, and earnings notes.

TriGemX Bio SPAC Merger: Late-Stage Migraine Bet Meets Cash Risk
TriGemX Bio is a clinical-stage biotech developing elismetrep for acute migraine, and it is going public through a merger with TCGX Acquisition Corp. The deal is expected to close in the first quarter of 2027, but the setup still hinges on redemptions, dilution, and whether Phase 3 execution stays on track.

Top Big Pharma Stocks: Our 5 Best Picks for October 2026
A five-stock big pharma countdown spans vaccines, oncology, immunology and MedTech, featuring Amgen, Pfizer and Johnson & Johnson among diversified names.

Talawar Tx SPAC Merger: A $120M Biotech Bet with Cash Clock
Talawar Tx is a preclinical biotechnology company developing bispecific antibodies for immunology and inflammatory diseases, and it is going public through a merger with JATT II Acquisition Corp. The deal points to a second-half-2026 close, with a big PIPE supporting the transaction, but shareholders should watch redemption risk and whether the cash stack still clears the minimum funding bar.
Want a deeper read on PFE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027
fool.com · Nov 20
Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?
zacks.com · Nov 20
5 High-Yield Dividend Stocks Retirees Can Buy for Under $50 a Share
247wallst.com · Nov 20
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
zacks.com · Nov 20
4 Dividend Stocks Wall Street Gave Up On With Balance Sheets Built to Recover
247wallst.com · Nov 20
Pfizer Yields 6.25%. These 3 Dividend Stocks Pay More Than a 1-Year Treasury Bill
247wallst.com · Nov 20
4 Yield Traps Paying Over 6% That Retirees Should Watch Out For
247wallst.com · Nov 20
PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies
zacks.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.